INIS
administration
14%
age groups
8%
arteries
17%
blood pressure
29%
cardiovascular diseases
14%
comparative evaluations
19%
control
6%
coronaries
51%
coronaviruses
15%
covid-19
14%
data
12%
developing countries
29%
devices
9%
diseases
24%
diuretics
14%
dna
14%
doors
23%
elevation
58%
females
5%
genes
29%
heart failure
17%
hospitals
24%
hypertension
24%
indonesia
25%
insulin
14%
interventions
43%
ischemia
8%
length
14%
levels
11%
management
14%
men
6%
methylation
14%
metropolitan areas
14%
morbidity
5%
mortality
60%
myocardial infarction
75%
patients
100%
performance
32%
physiology
14%
radiation exposure (doses)
5%
receptors
17%
risks
40%
screening
29%
strains
14%
substrates
14%
therapy
15%
units
43%
values
16%
vasopressin
5%
women
23%
Keyphrases
Acute Myocardial Infarction
14%
Acute ST-segment Elevation Myocardial Infarction
16%
Antihypertensive Medication
20%
Blood Pressure
24%
Blood Pressure Screening
14%
Cardiac Critical Care
14%
Cardiovascular Care
16%
Cardiovascular Intensive Care Unit
29%
Cardiovascular Risk
14%
Cataract
14%
Clopidogrel Resistance
14%
Coronavirus Disease 2019 Outbreak
14%
COVID-19
16%
CYP2C19 Polymorphism
14%
Developing Countries
29%
Diuretics
14%
DNA Hypomethylation
14%
Eptifibatide
14%
Gender Differences
16%
GLORIA-AF
14%
Heart Failure Management
14%
Hypertension
33%
Indonesia
42%
Indonesian
14%
Infarct-related Artery Patency
14%
Insulin Receptor substrate-1 Gene
14%
International Society of Hypertension
14%
Interventional Cardiology
21%
Ionizing Radiation Effects
14%
Major Adverse Cardiovascular Events
14%
May Measurement Month
29%
Mortality Prediction
29%
Multiple Imputation
15%
Myocardial Infarction Network
14%
Myocardial Infarction Patients
34%
Non-vitamin K Antagonist Oral Anticoagulants
14%
Peri-procedural
14%
Polymorphism
14%
Post-acute
14%
Primary Angioplasty
14%
Primary Percutaneous Coronary Intervention
43%
Protection Equipment
14%
Radiation Protection
14%
Radiation Workers
14%
Radiation-induced Cataract
14%
Screening Campaign
19%
ST-elevation Myocardial Infarction (STEMI)
63%
STEMI Network
14%
TIMI Flow
14%
Tolvaptan
14%
Medicine and Dentistry
Angioplasty
14%
Antihypertensive Agent
9%
Antithrombotic
14%
Awareness
14%
Blood Clot Lysis
7%
Blood Pressure
14%
Cardiovascular System
16%
Cataract
14%
Coronary Care Unit
43%
COVID-19
14%
Diastolic Blood Pressure
9%
Eptifibatide
14%
Hemodynamic
14%
Hospital Mortality
18%
Infarction
16%
Intensive Care
14%
Interventional Cardiology
18%
Ionizing Radiation
14%
Ischemia
8%
Logistic Regression Analysis
9%
Midazolam
18%
Myocardial Infarction
23%
Odds Ratio
11%
Percutaneous Coronary Intervention
14%
Prevalence
5%
Primary Percutaneous Coronary Intervention
29%
Radiation Exposure
14%
Radiation Protection
7%
Reperfusion Therapy
7%
SAPS II
14%
ST Segment Elevation Myocardial Infarction
31%
Systolic Blood Pressure
9%
Tertiary Care
9%
Vitamin K Antagonist
6%